|1st February 2021||Richard Peters||60,943||Grant/award etc.||$0.00|
|1st February 2021||Richard A. Heyman||1,959||Grant/award etc.||$0.00|
|1st February 2021||Cecil B Pickett||1,959||Grant/award etc.||$0.00|
|1st February 2021||N Anthony Coles||1,118||Grant/award etc.||$0.00|
|1st February 2021||Jeffery W. Kelly||1,959||Grant/award etc.||$0.00|
|1st February 2021||Paulash Mohsen||4,665||Grant/award etc.||$0.00|
|13th November 2020||N Anthony Coles||11||Exercise of derivative||$345.47||$3,800.17|
|17th August 2020||N Anthony Coles||2,453||Open or private sale||$156.77||$384,559.26|
|29th July 2020||N Anthony Coles||1,157||Grant/award etc.||$0.00|
|10th June 2020||Enterprise Associates 12, Limited Partnership New||1,482,809||Other acquisition or disposition||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Proteostasis Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It engages in the discovery and development of novel therapeutics to treat cystic fibrosis (CF) and other diseases.